31A Stock Overview
TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TheraVet SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.71 |
| 52 Week High | €2.64 |
| 52 Week Low | €0.67 |
| Beta | -0.26 |
| 1 Month Change | -24.09% |
| 3 Month Change | n/a |
| 1 Year Change | -73.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 31A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.9% | -5.1% | -2.0% |
| 1Y | -73.3% | -21.1% | -0.3% |
Return vs Industry: 31A underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 31A underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 31A volatility | |
|---|---|
| 31A Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 31A's share price has been volatile over the past 3 months.
Volatility Over Time: 31A's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 8 | Enrico Bastianelli | www.thera.vet/en |
TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET, an injectable self-hardening phosphocalcic bone void filler for osteointegration, osteoinduction, and bone remodeling properties; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid, species specific plasma, and an active pharmaceutical component.
TheraVet SA Fundamentals Summary
| 31A fundamental statistics | |
|---|---|
| Market cap | €2.51m |
| Earnings (TTM) | -€2.04m |
| Revenue (TTM) | €1.30m |
1.9x
P/S Ratio-1.2x
P/E RatioIs 31A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 31A income statement (TTM) | |
|---|---|
| Revenue | €1.30m |
| Cost of Revenue | €1.92m |
| Gross Profit | -€621.86k |
| Other Expenses | €1.42m |
| Earnings | -€2.04m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 12, 2024
| Earnings per share (EPS) | -0.63 |
| Gross Margin | -47.87% |
| Net Profit Margin | -156.99% |
| Debt/Equity Ratio | 15.0% |
How did 31A perform over the long term?
See historical performance and comparison